Literature DB >> 18452430

Distribution of p53 expression in tissue from 774 Danish ovarian tumour patients and its prognostic significance in ovarian carcinomas.

Estrid V S Høgdall1, Lise Christensen, Claus K Høgdall, Kirsten Frederiksen, Simon Gayther, Jan Blaakaer, Ian J Jacobs, Susanne K Kjaer.   

Abstract

The clinical roles played by normal and altered p53 in cancer are under intensive investigation, but larger studies describing the pattern as well as the prognostic value are still needed. The aim of this study was, using tissue array (TA), to examine the overexpression of p53 protein in 774 epithelial ovarian tumour tissues from Danish women and to evaluate whether p53 tissue expression levels correlate with clinicopathological parameters and prognosis. The distribution of p53 expression levels at different stages of disease, in different histological subtypes, and the prognostic value of p53 tissue expression were examined. Overall, p53 was expressed in 24/189 (13%) low malignant potential ovarian tumours (LMP) and in 278/585 (48%) ovarian cancers (OC). No significant difference in frequency of p53 tissue expression in LMP tissue was noted with increasing tumour stage (p=0.98). By contrast, there was a significant increase in the frequency of p53 tissue expression in OC with increasing FIGO stage (p<0.00001). Multivariate Cox regression analysis found that less than 20% tissue expression of p53 was associated with longer OC disease-specific survival. Tissue p53 expression may be of prognostic value in women with OC.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18452430     DOI: 10.1111/j.1600-0463.2008.00917.x

Source DB:  PubMed          Journal:  APMIS        ISSN: 0903-4641            Impact factor:   3.205


  9 in total

1.  Poor survival with wild-type TP53 ovarian cancer?

Authors:  Kwong-Kwok Wong; Daisy I Izaguirre; Suet-Yan Kwan; Erin R King; Michael T Deavers; Anil K Sood; Samuel C Mok; David M Gershenson
Journal:  Gynecol Oncol       Date:  2013-06-22       Impact factor: 5.482

Review 2.  Ovarian cancer in endometriosis: clinical and molecular aspects.

Authors:  B Lyttle; L Bernardi; M E Pavone
Journal:  Minerva Ginecol       Date:  2014-04

3.  Wild-type and mutant p53 mediate cisplatin resistance through interaction and inhibition of active caspase-9.

Authors:  Jacqueline L Y Chee; Suzan Saidin; David P Lane; Sai Mun Leong; Jacqueline E Noll; Paul M Neilsen; Yi Ting Phua; Hani Gabra; Tit Meng Lim
Journal:  Cell Cycle       Date:  2012-01-15       Impact factor: 4.534

4.  Predicting survival in head and neck squamous cell carcinoma from TP53 mutation.

Authors:  David L Masica; Shuli Li; Christopher Douville; Judith Manola; Robert L Ferris; Barbara Burtness; Arlene A Forastiere; Wayne M Koch; Christine H Chung; Rachel Karchin
Journal:  Hum Genet       Date:  2014-08-10       Impact factor: 4.132

5.  Evaluation of Preoperative Serum Levels of CA 125 and Expression of p53 in Ovarian Neoplasms: A Prospective Clinicopathological Study in a Tertiary Care Hospital.

Authors:  Ranjan Kumar Tiwari; Kaushik Saha; Debasis Mukhopadhyay; Chhanda Datta; Uttara Chatterjee; Tarun Kumar Ghosh
Journal:  J Obstet Gynaecol India       Date:  2014-10-07

6.  Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary.

Authors:  Ahmed Ashour Ahmed; Dariush Etemadmoghadam; Jillian Temple; Andy G Lynch; Mohamed Riad; Raghwa Sharma; Colin Stewart; Sian Fereday; Carlos Caldas; Anna Defazio; David Bowtell; James D Brenton
Journal:  J Pathol       Date:  2010-05       Impact factor: 7.996

Review 7.  Endometriosis and ovarian cancer: links, risks, and challenges faced.

Authors:  Mary Ellen Pavone; Brianna M Lyttle
Journal:  Int J Womens Health       Date:  2015-07-01

8.  Promoter methylation of IGFBP-3 and p53 expression in ovarian endometrioid carcinoma.

Authors:  Pao-Ling Torng; Ching-Wei Lin; Michael Wy Chan; Hui-Wen Yang; Su-Cheng Huang; Chin-Tarng Lin
Journal:  Mol Cancer       Date:  2009-12-11       Impact factor: 27.401

9.  Assessing mutant p53 in primary high-grade serous ovarian cancer using immunohistochemistry and massively parallel sequencing.

Authors:  Alexander J Cole; Trisha Dwight; Anthony J Gill; Kristie-Ann Dickson; Ying Zhu; Adele Clarkson; Gregory B Gard; Jayne Maidens; Susan Valmadre; Roderick Clifton-Bligh; Deborah J Marsh
Journal:  Sci Rep       Date:  2016-05-18       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.